KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) Q3 2014 Earnings Conference Call. November 10, 2014 4:30 PM ET. Executives. Heather Rowe – Director, IR. Keith Leonard – President and CEO KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of Get Kythera Biopharmaceuticals Inc historical price data for KYTH stock. Investing.com has all the historical stock data including the closing price, open, high, Prev. Open. High. Low. Volume, -. Latest news. 10/2015. Kythera
13 Sep 2013 How have hedgies been trading Kythera Biopharmaceuticals Inc Partner Fund Management has a $30.2 million position in the stock,
The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts. KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,604,168 shares of common stock, par value $0.00001 per share (the KYTH Stock Message Board for Investors. KYTHERA Biopharmaceuticals Inc. Stock Price, News and Company Updates. Message Board Total Posts: 39 Closing Stock Price USD 74.92: As of Date September 18, 2015: One Year Performance 106.90%: One Month Performance 0.33%: Industry Group Pharmaceuticals: Other: 52 wk. Range USD 29.86 - 76.311: Market Cap (Millions) USD 1,970.471: Total Shares Outstanding (Millions) 26.25: Latest Filing Dates: Annual December 31, 2014: Semi Annual N/A: Quarterly Kythera Biopharmaceuticals Inc Advanced Stock Charts, Monthly, Yearly, Stock Quotes - CSIMarket
Kythera Biopharmaceuticals Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Kythera Biopharmaceuticals Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st.
Stock price quotations are updated continuously. Click reload. to refresh this display. ,  and  stock price charts are available for Kythera Biopharmaceuticals InMarket data delivered to TradingCharts.com, Inc. by Barchart.com. Although it is believed that information provided is accurate, no guarantee is made. KYTHERA BIOPHARMACEUTICALS INC : News, information and stories for KYTHERA BIOPHARMACEUTICALS INC | Nasdaq: | Nasdaq New York. Guide. Premium. Free Registration. Sign In. My Desk Kythera Biopharmaceuticals Inc Daily Stock Prices Chart. This stock price chart for Kythera Biopharmaceuticals Inc, symbol KYTH, Nasdaq Stock Exchange is updated daily. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.This rally higher can be attributable to solid volume too with far more
Get instant access to a free live interactive chart for the Kythera Biopharmaceuticals Inc stock. You have the option to change the appearance of the charts by varying the time scale, chart type KYTH | Complete K. Kythreotis Holdings Public Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine.
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. Real-time trade and investing ideas on Kythera Biopharmaceuticals Inc. KYTH from the largest community of traders and investors.
17 Jun 2015 Allergan to buy double-chin treatment maker Kythera for $2.1 billion Botox maker Allergan PLC agreed to buy Kythera Biopharmaceuticals Inc., which is so-called double chins, for about $2.1 billion in cash and stock 23 Jul 2015 the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the $75 per share for each share of Kythera common stock they own. 17 Jun 2015 Allergan Chief Executive Brent Saunders at the New York Stock Exchange on June 15. His firm is buying Kythera Biopharmaceuticals Inc. 24 Jun 2020 Keith has made over 11 trades of the Unity Biotechnology Inc stock since and Chief Executive Officer of KYTHERA Biopharmaceuticals, Inc., Allergan, Inc. was an American global pharmaceutical company focused on eye care, On March 1, 2013, the company acquired MAP Pharmaceuticals Inc., Inc. announced it would acquire Kythera Biopharmaceuticals for around $2.1 billion SAN DIEGO , May 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. Chief Business Officer of Kythera Biopharmaceuticals, Inc. , from 2005 to 2010, and held grant to Mr. Munshi to purchase 3,800,000 shares of Arena common stock . The stock closed up 25.4% at $162.43 after the AbbVie deal was announced. For instance, the company paid $2.1bn for Kythera Biopharmaceuticals Inc. in